SCHEMBL21137918

SCHEMBL21137918

CCCC(=O)N[C@H]1C(O)O[C@H](COC(=O)OC(CO)CO)[C@@H](O)[C@@H]1O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PYGB P11216 1/20 0.41
▸ TLR4 O00206 2/20 0.38
▸ PRKD3 O94806 1/20 0.37
▸ PRKCG P05129 1/20 0.37
▸ PRKCB P05771 1/20 0.37
▸ PRKCA P17252 1/20 0.37
▸ PRKCH P24723 1/20 0.37
▸ PRKCI P41743 1/20 0.37
▸ PRKCE Q02156 1/20 0.37
▸ PRKCQ Q04759 1/20 0.37
▸ PRKCZ Q05513 1/20 0.37
▸ PRKCD Q05655 1/20 0.37
▸ PRKD1 Q15139 1/20 0.37
▸ LMNA P02545 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ MAPK1 P28482 2/20 0.36
▸ HK1 P19367 3/20 0.35
▸ HK2 P52789 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21137927 0.90 PYGB (0.41) PYGBTLR4PRKD3PRKCGPRKCB
SCHEMBL21058377 0.88 PYGB (0.40) PYGBTLR4PRKD3PRKCGPRKCB
SCHEMBL21138039 0.82 PYGB (0.45) PYGBTLR4PRKD3PRKCGPRKCB
SCHEMBL21137953 0.82 PYGB (0.45) PYGBTLR4PRKD3PRKCGPRKCB
SCHEMBL21137988 0.81 PYGB (0.40) PYGBTLR4LMNAKDM4ECYP2D6
SCHEMBL21138298 0.80 PYGB (0.53) PYGBTLR4LMNAKDM4ECYP2D6
SCHEMBL21138012 0.80 PYGB (0.53) PYGBTLR4LMNAKDM4ECYP2D6
Hydrochloric Acid SCHEMBL31353002 0.80 PYGB (0.41) PYGBTLR4PRKD3PRKCGPRKCB
SCHEMBL23104873 0.79 PYGB (0.48) PYGBTLR4PRKD3PRKCGPRKCB
SCHEMBL21138044 0.79 PYGB (0.48) PYGBTLR4PRKD3PRKCGPRKCB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11718636-B2 Glucosamine derivatives for the prevention or treatment of joint disorders Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2023-08-08 — — US disclosed
US-20230227488-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2023-07-20 — — US disclosed
US-11591358-B2 Glucosamine derivatives and pharmaceutical uses thereof Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2023-02-28 — — US disclosed
US-20190185502-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN (SUZHOU) PHARMA TECH CO, LTD. (CN) 2019-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718636-B2 Glucosamine derivatives for the prevention or treatment of joint disorders OGT, UGGT1, GLA PYGB 760/4885TLR4 660/4885PRKD3 3161/4885
US-20230227488-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF OGT, UGGT1, GLA PYGB 601/4885TLR4 896/4885PRKD3 3037/4885
US-20190185502-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF OGT, UGGT1, GLA PYGB 601/4885TLR4 896/4885PRKD3 3037/4885
US-11591358-B2 Glucosamine derivatives and pharmaceutical uses thereof OGT, UGGT1, GLA PYGB 601/4885TLR4 896/4885PRKD3 3037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback